Ultrasound technology developer Mobisante has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MobiUS smartphone-based ultrasound imaging system.
Utilizing a smartphone and cloud-based Internet services, MobiUS is indicated for fetal/ob, abdominal, cardiac, pelvic, pediatric, musculoskeletal, and peripheral vessel imaging, according to the Redmond, WA-based firm. It can be used in primary and specialty care, Mobisante said.
MobiUS can employ cellular networks or Wi-Fi to send images to a remote expert for diagnosis or second opinion, as well as to a PACS for storage, the company said.
